Earnings Feed
Start Free
VIEMED HEALTHCARE, INC.·4

Jan 21, 5:00 PM ET

Trahan Jeremy 4

Research Summary

AI-generated summary

Updated

Viemed (VMD) GC Jeremy Trahan Exercises Derivatives, Receives Awards

What Happened

  • Jeremy Trahan, General Counsel of Viemed Healthcare (VMD), exercised/converted derivative awards on Jan 17, 2026 and had shares withheld/sold to cover taxes and cash-settled phantom awards. Specifically, the filing shows 4,884 and 1,221 derivative units exercised/converted, with 1,595 shares withheld for taxes (1,595 x $7.33 = $11,691) and 1,221 shares disposed to the issuer for cash settlement (1,221 x $7.33 = $8,950). On Jan 19, 2026 Trahan was granted new awards totaling 62,950 derivative units (50,360 + 12,590) shown as RSUs and phantom-share awards (no cash paid).

Key Details

  • Transaction dates: exercises/conversions and tax withholding/settlements on 2026-01-17; grants on 2026-01-19. Filing date: 2026-01-21.
  • Prices/values: tax-withheld 1,595 shares at $7.33 = $11,691; disposition to issuer 1,221 shares at $7.33 = $8,950. Some derivative exercises are reported with $0 per share (typical for conversions/phantom settlements).
  • Shares owned after these transactions: not specified in the provided filing details.
  • Notable footnotes:
    • RSUs = contingent right to one common share upon vesting (F1, F5, F7).
    • Shares were withheld to satisfy tax obligations from RSU vesting (F2).
    • Phantom shares are cash-settled rights equal to the economic value of one share; settlement is reported as acquisition of underlying shares and simultaneous sale back to the company for cash (F4, F6, F8, F9).
    • Grants dated Jan 19 vest in three equal annual installments beginning on the first anniversary of the grant date (F5, F6, F7, F9).
  • Transaction codes: M = exercise/conversion of derivative; F = tax withholding; D = disposition to issuer (cash settlement); A = award/grant.

Context

  • This was largely administrative: conversion/exercise of derivative awards and tax withholding/cash settlement of phantom units and RSUs, followed by new RSU/phantom grants. The disposals appear to be internal/cash-settlement and tax-related rather than open-market sales; such transactions typically reflect routine vesting and settlement rather than an outright market sale or independent buy signal.